Results 141 to 150 of about 19,263 (243)

Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery [PDF]

Julian Mehl, Dilara Akhoundova, Ulrike Bacher, Barbara Jeker, Gaëlle Rhyner Agocs, Axel Ruefer, Susanne Soltermann, Martin Soekler, Annette Winkler, Michael Daskalakis, Thomas Pabst   +10 more
openalex   +1 more source

Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab. [PDF]

Discov Med (Singap)
Subramanian NG, Aung FM, Hunzeker ZE, Patel KK, Lee HC, Jin S, Young E, Bassett RL, Rojas Hernandez CM.   +8 more
europepmc   +1 more source

Successful treatment of scleromyxoedema with daratumumab [PDF]

Katharina Epp, Raphael Teipel, Ulrike Reuner, Martin Bornhäuser, Claudia Günther, Karolin Trautmann‐Grill   +5 more
openalex   +1 more source

MajesTEC-3: Redefining what's possible in multiple myeloma. [PDF]

Clin Hematol Int
Al Hadidi S, Gaballa M.
europepmc   +1 more source

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

Decision letter for "Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients"

, 2021

openalex   +1 more source

Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible. [PDF]

Oncol Ther
Smith E, Camera A, Bird A.
europepmc   +1 more source

Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves\u27 disease [PDF]

\ua9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. INTRODUCTION: Severe Graves\u27 disease is a life-changing condition with poor outcomes from currently available treatments.
Bibby I, Bradley P, Cole M, Grixti L, Maier RH, McGregor N, Pearce SH, Walker J, Wason J, Wolstenhulme F   +9 more
core  

Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab

, 2023
Yuyuan Li, Chengyao Li, Ling Zhang, Jiao Li, Qixin Li, Haining Ouyang, Jiaona Luo, Lin-Rui Zhu, Kui Cai   +8 more
openalex   +1 more source

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. [PDF]

Ann Hematol
Wang Y, Chen X, Liang Q, Wang W, Luo J, Luo L, Feng R, Wei Y, Tian Y, Du X, Huang Z, Hu G, Fu X, Tao S, Zhou J, Peng H, Su Y, Zhang H, Dong M, Lan M, Sun Z, Wang X, Zhou H, Zhong L, Peter Gale R, Liang Y, Xia Z.   +26 more
europepmc   +1 more source